Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S.